Ö. Ataman

1.0k total citations
23 papers, 539 citations indexed

About

Ö. Ataman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ö. Ataman has authored 23 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Ö. Ataman's work include Lung Cancer Treatments and Mutations (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Advanced Radiotherapy Techniques (4 papers). Ö. Ataman is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Advanced Radiotherapy Techniques (4 papers). Ö. Ataman collaborates with scholars based in United Kingdom, Türkiye and United States. Ö. Ataman's co-authors include Shampa Das, David M. Wilson, Paul K. Stockman, Geoffrey I. Shapiro, Martijn P. Lolkema, David S. Boss, Jan H.M. Schellens, Emile E. Voest, Petronella O. Witteveen and Glenwood Goss and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Ö. Ataman

23 papers receiving 531 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ö. Ataman United Kingdom 14 313 181 169 120 78 23 539
József Lövey Hungary 12 168 0.5× 153 0.8× 90 0.5× 19 0.2× 12 0.2× 46 406
Prakash Peddi United States 13 282 0.9× 129 0.7× 201 1.2× 37 0.3× 11 0.1× 33 560
Manali Rupji United States 13 165 0.5× 111 0.6× 186 1.1× 33 0.3× 59 0.8× 45 479
Masako Uno Japan 12 148 0.5× 87 0.5× 180 1.1× 15 0.1× 72 0.9× 38 528
João Soares Nunes Brazil 11 149 0.5× 57 0.3× 202 1.2× 42 0.3× 36 0.5× 21 468
Roy Herbst United States 7 142 0.5× 119 0.7× 89 0.5× 16 0.1× 12 0.2× 12 329
Briant Fruth United States 10 547 1.7× 281 1.6× 169 1.0× 28 0.2× 60 0.8× 28 781
Jane‐Chloé Trone France 10 165 0.5× 142 0.8× 150 0.9× 28 0.2× 4 0.1× 43 501
Amy Prawira Canada 11 326 1.0× 147 0.8× 172 1.0× 13 0.1× 7 0.1× 38 621
Edith Rodríguez-Braun Spain 11 331 1.1× 154 0.9× 157 0.9× 105 0.9× 8 0.1× 21 478

Countries citing papers authored by Ö. Ataman

Since Specialization
Citations

This map shows the geographic impact of Ö. Ataman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ö. Ataman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ö. Ataman more than expected).

Fields of papers citing papers by Ö. Ataman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ö. Ataman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ö. Ataman. The network helps show where Ö. Ataman may publish in the future.

Co-authorship network of co-authors of Ö. Ataman

This figure shows the co-authorship network connecting the top 25 collaborators of Ö. Ataman. A scholar is included among the top collaborators of Ö. Ataman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ö. Ataman. Ö. Ataman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hong, David S., Aparna R. Parikh, Geoffrey I. Shapiro, et al.. (2020). First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. Journal for ImmunoTherapy of Cancer. 8(1). e000222–e000222. 54 indexed citations
2.
Velde, Helgi van de, Anil Londhe, Ö. Ataman, et al.. (2016). Association between complete response and outcomes in transplant‐eligible myeloma patients in the era of novel agents. European Journal Of Haematology. 98(3). 269–279. 20 indexed citations
3.
Ludwig, Heinz, Richard Greil, Tamás Masszi, et al.. (2015). Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up. British Journal of Haematology. 171(3). 344–354. 21 indexed citations
4.
Dimopoulos, Meletios Α., Robert Z. Orlowski, Pieter Sonneveld, et al.. (2014). Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 100(1). 100–106. 23 indexed citations
5.
Dimopoulos, Meletios Α., Robert Z. Orlowski, Thierry Façon, et al.. (2013). Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM). Blood. 122(21). 3177–3177. 2 indexed citations
6.
Schwartz, Gary K., Richard D. Carvajal, Rachel Midgley, et al.. (2012). Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Investigational New Drugs. 31(2). 370–380. 61 indexed citations
7.
Ataman, Ö., et al.. (2012). The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective. International Journal of Radiation Oncology*Biology*Physics. 84(4). e447–e454. 28 indexed citations
8.
Boss, David S., Petronella O. Witteveen, Martijn P. Lolkema, et al.. (2010). Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Annals of Oncology. 22(2). 431–437. 85 indexed citations
9.
Ataman, Ö., et al.. (2010). How to determine margins for planning target volume (PTV): From 2D to 3D planning in radiotherapy for head and neck cancer? Portal imaging assessment for set-up errors. 1 indexed citations
10.
Filleron, Thomas, A. John Barrett, Ö. Ataman, & A. Kramar. (2009). Planning Posttherapeutic Oncology Surveillance Visits Based on Individual Risk. Medical Decision Making. 29(5). 570–579. 3 indexed citations
11.
Alıcıkuş, Zümre Arıcan, et al.. (2008). Importance of patient, tumour and treatment related factors on quality of life in head and neck cancer patients after definitive treatment. European Archives of Oto-Rhino-Laryngology. 266(9). 1461–1468. 25 indexed citations
12.
Akman, Fadime, Ö. Ataman, Ahmet Ömer İkiz, et al.. (2008). The impact of treatment center on the outcome of patients with laryngeal cancer treated with surgery and radiotherapy. European Archives of Oto-Rhino-Laryngology. 265(10). 1245–1255. 14 indexed citations
13.
Davidson, S.E., et al.. (2007). Improving the Capture of Adverse Event Data in Clinical Trials: The Role of the International Atomic Energy Agency. International Journal of Radiation Oncology*Biology*Physics. 69(4). 1218–1221. 30 indexed citations
14.
15.
Ataman, Ö., Søren M. Bentzen, George D. Wilson, et al.. (2004). Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer. European Journal of Cancer. 40(18). 2734–2741. 20 indexed citations
16.
Ataman, Ö., Ann Barrett, S.E. Davidson, et al.. (2004). Audit of effectiveness of routine follow-up clinics after radiotherapy for cancer. Radiotherapy and Oncology. 73(2). 237–249. 15 indexed citations
17.
18.
Ataman, Ö., et al.. (2001). Optimization in high dose rate brachytherapy for utero-vaginal applications. Radiotherapy and Oncology. 58(1). 31–36. 14 indexed citations
19.
Ataman, Ö., et al.. (2000). KANSER HASTALARINDA TIP DIŞI TEDAVİ YÖNTEMLERİNİN ARAŞTIRILMASI. 14(3). 245–249. 1 indexed citations
20.
Ataman, Ö., et al.. (1998). 83 Rectum dose analysis of intracavitary applications in gynecological cancer. Radiotherapy and Oncology. 47. S21–S21. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by József Lövey Breakdown of academic impact, for papers by Prakash Peddi Breakdown of academic impact, for papers by Manali Rupji Breakdown of academic impact, for papers by Masako Uno Breakdown of academic impact, for papers by João Soares Nunes Breakdown of academic impact, for papers by Roy Herbst Breakdown of academic impact, for papers by Briant Fruth Breakdown of academic impact, for papers by Jane‐Chloé Trone Breakdown of academic impact, for papers by Amy Prawira Breakdown of academic impact, for papers by Edith Rodríguez-Braun
Rankless by CCL
2026